CHARLOTTE FERRELL SMITH
cancer.A secondary endpoint of the EMILIA study was time to symptom worsening (time from randomization to the first documentation of a ≥ 5-point decrease from baseline) as measured by the Trial Outcome Index Physical/Functional/Breast (TOI-PFB) subset of the Functional Assessment of Cancer ...
a The attitude of a cancer patient who is receiving radiation therapy, an X-ray treatment, can become more positive. The physician who is following Simonton's psychological treatment plan suggests that the patient imagine that he or she can see the tumor(肿瘤)in the body. In the mental pict...
Now investigators are diligently working to determine which of these agents is suitable for a given patient in each disease setting in the HER2-positive space and developing new agents and combinations to further improve efficacy without increasing toxicity. During a recent OncLive Peer Exchange, exper...
tucatinib instead. For a patient who has active or previously treated CNS [central nervous system] metastases, I would likely go for tucatinib as the preferred regimen first, then switch to T-DXd at the time of progression. It’s shared decision-making between myself and the patient when we...
Effective targeting of the human epidermal growth factor receptor 2 (HER2) has changed the natural history of HER2 overexpressing (HER2+) metastatic breast cancer. The initial success of trastuzumab improving time to progression and survival rates led to the clinical development of pertuzumab, ado-tra...
Our team is not only passionate about racing—we band together to carry a positive message to others who struggle with cancer. We aim to educate and support the community by sharing our stories and inspiring others to live the best life possible. ...
Participants responded to online research postings on the non-profit organization Facing Our Risk of Cancer Empowered’s (FORCE) message board and social media pages as well as HBOC-specific Facebook groups. The interview data were coded using the constant comparison method. Results Two major ...
CARTITUDE-4 study authors concluded that “in the context of longer-term data from cohort A of the CARTITUDE-2 study in a similar patient population, these results support the potential for prolonged disease control and the benefit of ciltacel for patients with multiple myeloma as early a...
We assessed health-related quality of life (symptoms of therapy/patient functioning/global health status), in APHINITY (pertuzumab/placebo, trastuzumab, and chemotherapy as adjuvant HER2-positive early breast cancer therapy). Patients received 1 year/18